Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Healthcare Industry’s First Carbon Tech Platform Launched by Zasti

Zasti

Zasti, an advanced analytics enterprise that offers carbon tech solutions and strong environmental, social, and governance (ESG) values to the United States healthcare marketplace, announced it is collaborating with Change Healthcare (NASDAQ: CHNG), a health care technology leader. The two companies are aiming to build efficiencies and reduce carbon emissions generated by the healthcare industry. Combining billions of data points from Change Healthcare with Zasti’s AI technology allows users to Assess, Target, Optimize, and Monitor ( ATOM TM ) carbon emissions. “Working with Change Healthcare to deploy ATOM throughout the healthcare industry will allow organizations to be more efficient as decarbonization strategies are considered and implemented” explained Krish R. Krishnan, Zasti’s CEO. “The healthcare industry is responsible for a tenth of all greenhouse gas emissions, making it a focal point for stakeholder scrutiny”. Zasti’s ATOM provides precise measurement of direct and indirect carbon emissions via a proprietary healthcare carbon database. With this data, carbon emission hotspots are identified using pre-designed algorithms providing uses with an AI-driven decarbonization strategy. “The power of our collaboration is combining real-world data that is already processed by Change Healthcare with Zasti’s ATOM platform,” said Tim Suther, senior vice president and general manager of Data Solutions at Change Healthcare. “A provider’s carbon baseline can be quickly established with visibility into how individual procedures and activities contribute to carbon emissions. The ATOM platform then provides benchmarks and actionable insights to reduce those emissions. Real-time data-driven actions can then facilitate carbon emission reductions.” Zasti’s ATOM AI technology offers solutions that achieve continuous optimization and offsetting of carbon emissions. It also tracks the real-time progress of emission reductions through a user-friendly dashboard that integrates with accounting, sustainability, and disclosure details. Dr. David Chang, leading cataract surgeon at the Peninsula Eye Surgery Center in Northern California shared his perspective by stating, “The carbon footprint of the healthcare sector in general, and the operating room in particular, is surprisingly large. We have an important opportunity to make an impact by being more green and by reducing needless OR waste.” “Like all industries today, healthcare too must accelerate the decarbonization process. No industry, especially healthcare, is immune from the responsibility to strive for achieving net-zero emissions. Nor can an industry dodge the looming regulations imposing a plan and the actions moving toward net-zero emissions”, Krishnan, also a Delegate to COP26, stated. “Our collaboration with Change Healthcare is a major step in revolutionizing the healthcare industry by making it sustainable.” About Zasti The Zasti proprietary carbon emission metrics database and AI platform offer a granular, accurate baselining of emission and configurable ESG (Environmental, Social, & Governance) compliance reports. The Zasti AI analytics suite provides management teams with fact-based, real-time, actionable insights that deliver meaningful progress toward meeting decarbonization goals. To automate your decarbonization goals, visit https://www.zasti.ai/ ### For more information or to schedule an interview with Krish Krishnan, contact Dan Rene at 202-329-8357 or daniel.rene@kglobal.com. Contact Details kglobal Dan Rene +1 202-329-8357 daniel.rene@kglobal.com Company Website https://zasti.ai/

November 11, 2021 10:00 AM Eastern Standard Time

BIOSAPIEN CLOSES $1.8M SEED ROUND LED BY SOSV & HIKMA VENTURES

Biosapien

BioSapien, a biotech company has announced it has raised $1.8M in seed round funding led by global venture capital investor SOSV. Co-investors in the round include Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, and other high-net worth angels and investors (Additional investors listed below*). In addition to the seed round funding, a non-dilutive grant of $256K from the National Science Foundation will accelerate the development of BioSapien’s patented product, MediChip ™: a 3D printed biodegradable mesh chip designed to deliver cancer drugs directly to the tumor site while reducing side effects. “It’s great to have the support of these esteemed investors in BioSapien,” says Dr. Khatija Ali, CEO and co-founder of BioSapien. “The seed round funds will advance development of MediChip ™ and give access to global distribution channels and manufacturing. Chemotherapy can cause devastating side effects for patients. MediChip ™ is designed to deliver cancer drugs straight to hard-to-reach tumor sites, for increased efficacy with reduced toxicity.” MediChip ™ is a novel biodegradable drug delivery platform designed to precisely administer any type of FDA-approved drug, locally and in a sustained manner. Pre-clinical research shows that in comparison to systemic chemotherapy, MediChip ™ mitigates systemic side-effects through localized controlled release. For cancer indications, it has the potential to improve the patient’s quality of care and life. It is designed to be a first-line treatment option for stage III locally advanced gastrointestinal cancer patients during surgery for adjuvant chemotherapy delivery. MediChip ™ was granted its patent in February 2021 with a priority date of December 21, 2018. Potential For Stage III, IV Pancreatic Cancer The current clinical pipeline includes BioSapien’s lead indication of pancreatic cancer and others including lung cancer, esophageal cancer, and colorectal cancer. There are approximately 57,000 new cases of pancreatic cancer in the US every year. Founded in 2018, in New York City, NY, BioSapien has already garnered global attention. In addition to the seed round funding and NSF grant which Inspiralia assisted in securing, BioSapien has been recognized in high profile biotech pitch competitions, winning the Pitch Night by Amazon and the Get in the Ring Start Up Competition. The company is currently a semi-finalist in the PacBio 2021 conference. Now, with backing from SOSV, Hikma, and JPIN VCATS, MediChip ™ has strategic partners, financial backing, and global reach to progress towards achieving the goal of impacting patient care worldwide. * Additional investors include; SOSV, Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, Harbr, Beni VC, Cedas Foundation, Kartik Garg - The Modern Nomad, George and Saul, and other angels About BioSapien BioSapien Inc. is a venture-backed biotechnology company focused on innovative therapies to transform patient care. The company invented MediChip ™: a patented treatment that early research has shown can reduce the system-wide side effects of cancer chemotherapy treatments. The 3D printed biodegradable mesh is designed to allow for a more exact delivery of already approved FDA pharmaceuticals without the adverse effects. For more information, visit www.biosapien.com. About SOSV SOSV is a global venture capital firm headquartered in Princeton, NJ. The firm has more $900 million in assets under management and more than 1,000 portfolio companies. SOSV operates the startup development programs HAX (hard tech), IndieBio (life sciences), Chinaccelerator and MOX (cross-border growth in Asia) and dlab (blockchain). Sean O'Sullivan, a serial entrepreneur and technologist, is the founder of SOSV. The firm has 8 general partners and a 130-person staff across seven locations in the US, Europe and Asia. About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, Hikma has been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, Hikma is a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and uses their unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. Hikma is committed to their customers, and the people they care for, and by thinking creatively and acting practically, Hikma provides them with a broad range of branded and non-branded generic medicines. Together, Hikma’s 8,600 colleagues are helping to shape a healthier world that enriches everyone’s communities. Hikma is a leading licensing partner, and through their venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com. About Hikma Ventures Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com. About Biosapien Biosapien Inc. is a venture-backed biotechnology company focused on innovative therapies to transform patient care. The company developed MediChip ®: a patented treatment that reduces the system-wide side effects of cancer chemotherapy treatments. The 3D printed biodegradable mesh allows for a more exact delivery of already approved FDA pharmaceuticals without the adverse effects Contact Details WantLeverage Communications Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://biosapien.com/

November 11, 2021 08:03 AM Eastern Standard Time

Helping Seniors Feel Less Isolated and More Connected

YourUpdateTV

The ongoing pandemic has increased the likelihood that seniors feel more isolated, making tech-savviness both essential and a determinant of health. Recently, Senior Director at Care.com, Jill McNamara, teamed with YourUpdateTV on a satellite media tour to discuss the importance of getting seniors actively engaged online through technology. A video accompanying this announcement is available at: https://youtu.be/nNHYsVdQjZY The COVID-19 pandemic continues to challenge our aging population in numerous ways. They are feeling more isolated than ever and helping them stay engaged and socially connected has never been more important. According to Care.com’s 2021 Senior Care Outlook Survey, while aging in place remains their preference, the prolonged crisis has increased their desire to have more help at home. This results in a dire need to hire help with tasks within the home, such as meal preparation and light housekeeping. Both of these pandemic challenges are making tech-savviness essential and a key determinant of our seniors’ emotional and physical health going forward. This is why Care.com, the world’s leading online platform for finding family care, and GetSetUp, the largest social learning platform that helps older adults learn new skills and have new experiences, are collaborating to offer live online caregiving classes, such as how to find and pay for the care they need. Through this partnership, GetSetUp and Care.com will help older adults overcome any fears and reluctance they have in using tech to enhance their overall well-being. For those interested in learning more, please visit www.getsetup.org and search ‘ Care.com ’. About Jill McNamara: Jill McNamara is the Senior Director of Care@Work for Care.co m, the world’s largest online destination for finding and managing high-quality family care. Since joining Care.com in 2011, Jill has expanded the company’s senior care services nationally, and has assisted in growing the Senior Care Planning program for Care.com ’s enterprise arm Care@Work, which builds customized family care benefits packages for employers supporting the caregiving responsibilities of their employees. The program provides families with customized and comprehensive guidance, strategies, and local resources to meet individual needs. Jill started her social work career working with adults with mental and physical disabilities and continued to provide in-home counseling in and around the Boston area to families facing an array of complex challenges. Guided by her professional and personal experiences in senior care, she is extremely passionate about helping families and individuals navigate their own journey in senior care. Jill has her Masters in Social Work, is a Licensed Independent Clinical Social Worker, and a Certified Advanced Social Work Case Manager. She received her Bachelor of Arts degree in Social Work from Gordon College and obtained her Master of Social Work from Simmons College School of Social Work. About GetSetUp: GetSetUp is on a mission to help those over 55 learn new skills, connect with others and unlock new life experiences. The social learning platform helps over 3 million older adults in 160 countries stay mentally and physically fit, creates economic opportunities through jobs and reskilling, and provides a community where people find meaning and purpose by sharing their knowledge and passions and forming new connections. Classes are taught by older adults on a highly interactive, custom-built video platform where older adults can connect during and in between classes. Classes are taught in English, Spanish, Hindi, and Mandarin. Learn more at https://www.getsetup.org About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 10, 2021 05:00 PM Eastern Standard Time

Video

Powering Through a Sore Throat: Understanding the Symptoms and Seeking Relief

YourUpdateTV

From a first date to a big audition, to an important presentation, having a sore throat can easily put a damper on important moments and your everyday life. Recently, Family Medicine Physician, Dr. Jennifer Caudle, teamed with Mucinex and YourUpdateTV on a satellite media tour to discuss how to relieve sore throat symptoms. With another cold and flu season upon us, we know the impact of symptoms like cough, body aches, fever and more can really impede on our everyday lives. Recent findings show that sore throat pain is one of the top three most debilitating symptoms alongside fever and migraine. To better understand the impact sore throat pain has on people’s lives, Mucinex surveyed 2,005 U.S. adults in partnership with One Poll* about their experiences coping with it. Despite this, 55% of people are most likely to “power through” a sore throat—meaning they would continue working, going to school, running errands, completing housework, etc. while dealing with difficult sore throat pain. While cold and flu season can be so unpredictable each year, there are many over-the-counter medications that can be of help in relieving those unpleasant symptoms. For instance, Mucinex recently introduced Mucinex InstaSoothe, a new product line of lozenges and sprays designed to numb, soothe and relieve that sore throat pain. The lozenges contain ingredients like Hexylresorcinol (also known as Hex), a local anesthetic for topical use on the mucous membranes, which helps to deliver that ‘numbing’ effect to throat and mouth, providing that much needed relief. The holiday season adds more to-dos and pressure, causing us to set high expectations and race to accomplish tasks. According to Dr. Caudle, if your energy is low, simply rest and take the time you need to focus on important tasks. Keep those vitamins handy and be sure to fuel your body with the right nutrients to help maintain a healthy immune system. Finally, for those of you back at work or school, be sure to bundle up in the colder weather, wear a mask, wash your hands and remember to continue social distancing. People must use over-the-counter products as directed. If your symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. For more information on how to power through this cold and & flu season, visit Mucinex.com. About Dr. Jennifer Caudle: Dr. Jen Caudle is a board-certified family medicine physician and associate professor in the department of Family Medicine at Rowan University-School of Osteopathic Medicine. She appears regularly as an on-air health expert for local and national news outlets, including ‘The TODAY Show’, CNN, FOX News, PBS, Fox 29 Philadelphia News, and many others. Dr. Jen’s health articles have been published in The Daily Beast, CNN.com, and ABCNews.com, among others. Dr. Jen graduated with honors from Princeton University and earned her medical degree from UMDNJ – School of Osteopathic Medicine. About the Survey*: This random double-opt-in survey of 2,005 Americans was commissioned by Mucinex between August 26 and August 30, 2021. It was conducted by market research company OnePoll, whose team members are members of the Market Research Society and have corporate membership to the American Association for Public Opinion Research ( AAPOR ) and the European Society for Opinion and Marketing Research ( ESOMAR ). About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 09, 2021 05:00 PM Eastern Standard Time

Video

Microban® International Announces a New Range of Antiviral Technologies

Microban International

Microban International, the global leader in antimicrobial solutions, odour control and residual sanitisation/disinfection solutions, is pleased to announce a new range of antiviral technologies that are proven to reduce viral loading on products and surfaces. Microban has long been a trusted partner in a wide range of sectors – from consumer and healthcare to industrial and construction – and this announcement adds to the versatility of the company’s technology portfolio. Microban ® technology can be incorporated into various materials during manufacturing, becoming part of the product’s structure to provide inherent and enduring protection from microbes. Recent data demonstrates that new antiviral technologies from Microban conform to both ISO 18184 – which assesses the antiviral performance of treated textile products, such as woven and knitted fabrics, fibres, yarns, and braids – and ISO 21702, which measures activity in treated plastics and other non-porous surfaces. Thorough testing was performed to evaluate the efficacy of each product type against many viruses, including bacteriophage Phi6, an important surrogate virus for SARS-CoV-2. The results showed that articles treated with these technologies can now benefit from reduced viral loading* by up to 99 %. Antiviral technologies from Microban inhibit the viruses’ ability to remain viable on surfaces. The modes of action vary, disrupting the structure of either the outer protein coat – to prevent viruses from recognising or binding to host cells – or nucleic acid payload, to prevent viral replication. This gives manufacturers a valuable product feature and provides consumers with added peace of mind. Michael Ruby, President of Microban International, explained: “We are excited with the latest results confirming the antiviral activity of our new technologies. Assessing antiviral efficacy in treated products to a standard that meets the complex regulatory landscape is an arduous process, but we have been confident throughout that our innovative solutions conformed to the rigorous ISO standards. Our world-class research team and global in-house regulatory department worked diligently to ensure that the technology is recognised as effective and compliant across various markets, to support partners with their claims and give customers even greater confidence in products protected with Microban antiviral technology.” Following the start of the COVID-19 pandemic, there was a monumental upsurge in demand for antiviral technology in products and it is readily acknowledged that Microban was not the first in the industry to make antiviral claims. Instead, the company invested a considerable amount of time and resources to ensure that its antiviral technologies were not only scientifically proven to be effective in reducing viral loading on surfaces and products, but that they could also be used in a regulatory compliant manner by brands and manufacturers across a variety of territories and product types. Microban is committed to being a reliable and trusted industry leader, and its unrivalled regulatory expertise can help to ensure that partners are aware of the implications that antiviral claims can have on their product types in the countries where they are being sold. For more information on Microban’s new range of antiviral technologies and registration requirements in your territory, visit www.microban.com/antiviral/technologies or contact your Microban representative. *Antiviral efficacy may vary depending on substrate type, application dosage of the treatment, impurities, and application procedure. Only Microban antiviral technologies that are registered with US EPA and are EU BPR compliant are being offered for sale. In the US, antiviral technologies may only be incorporated into products that are or will be registered with the US EPA. Contact your Microban representative for further information. About Microban International: Part of Barr Brands International (BBI), Microban International is home to the most trusted and well-known global brands in the antimicrobial, odour control, and sanitisation / disinfection markets – Microban ® and Ultra-Fresh ®. Our organisation has experienced over 100 collective years of growth and has revolutionised the industry. As the global leader, our proactive systems keep products cleaner, and control odours better by preventing problems before they start. Microban International drives innovation by combining science and creative solutions that enhance high-quality consumer, textile, industrial and medical products around the world. Today, the Microban and Ultra-Fresh brands and our technologies are featured on thousands of products worldwide. The company is headquartered in North Carolina with operations in North America, Europe, and Asia Pacific. For more information, please visit www.microban.com. © 2021 kdm communications limited Editorial contact for further information or follow-up Sarah Khan or Audrey Jestin at kdm communications limited, St Neots, UK Tel. +44 (0) 1480 405333 Fax: +44 (0) 1480 477833 Contact Details kdm communications limited Sarah Khan +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com

November 09, 2021 07:01 AM Eastern Standard Time

Image

VinFuture foundation hosts public dialogue about "Renewable energy & new materials for the future" with Nobel-Winning professor

Vingroup

VinFuture Foundation will hold its Online Science Dialogue series’ second installment discussing “Renewable energy and new materials for the future" on November 12th, 2021. The Dialogue will see the attendance of world-class scientists, most notably Professor Konstantin (Kostya) Sergeevich Novoselov, a Nobel Prize laureate in Physics. The event is aimed at bringing science and technology closer to the general public with solutions that have high real-world applicability. HANOI, VIETNAM - Media OutReach - 8 November 2021 - This November, VinFuture 's Dialogue is titled "Renewable energy and new materials for the future" and centers around foundational knowledge and applications of new energy and materials in humanity's response to the global energy crisis. As part of the program, young scientists will also have chances to converse with world-leading scientists, and to discuss the opportunities and challenges they encounter in their start-ups, thereby bringing research projects into industrial production and out into the world. Most notably, leading the discussion on "Future materials" will be the Nobel Prize laureate in Physics - Professor Konstantin (Kostya) Sergeevich Novoselov. As the youngest scientist to have been awarded the Nobel Prize in Physics since 1973, Prof. Novoselov has a global influence in condensed matter physics and nanotechnology. His achievements with graphene - the strongest ultra-thin material in human knowledge - promise to deeply change the fields of Science and Technology, Industry, and Medicine. Prof. Novoselov is currently a Fellow of the Royal Society, a member of the US National Academy of Science, as well as the National University of Singapore's Tan Chin Tuan Centennial Professor and Director of the Institute for Functional Intelligent Materials. Since 2014, Prof. Kostya Novoselov has always been featured as one of the most cited scientists globally and as part of the world's top 0.01% in the field of Science and Nanotechnology (PLOS, 2021). Professor Nguyen Thuc Quyen, Director for Polymers and Organic Solids, Professor in the Department of Chemistry & Biochemistry at the University of California, Santa Barbara (UCSB), will speak at the Dialogue on the topic of solar energy. With more than 418 research projects and 24 patents on renewable energy, electronic - organic devices, solar cells and photovoltaics, etc., Prof. Thuc Quyen was one of the world's most influential scientific minds and Top 1% Highly Cited Researchers in Materials Science according to Thomson Reuters and Clarivate Analytics for 5 consecutive years, from 2015 to 2019. Dr. Corey Hoven, Founder and CTO of Next Energy Technologies, will bridge the gap between scientific research and practical application. His company has successfully commercialized smart windows that can generate electricity for high-rise buildings using solar energy. VinFuture's Science Dialogue series aims to provide a space for open dialogue with the public, spreading the values of "science at the service of humanity" and contributing to the United Nations' 17 Sustainable Development Goals (SDGs). The Dialogue gives special attention to undergraduates, postgraduates, scientists, and young technology entrepreneurs in Vietnam and around the world. They will have the opportunity to share new perspectives, discuss breakthrough ideas, and raise their concerns about research topics or start-up projects and innovations in order to be discussed and addressed by the guest speakers. Dr. Le Mai Lan, Vice Chairman of Vingroup and Representative of VinFuture Foundation, shared: "Through the public dialogue series, we hope that leading scientists and researchers around the world can share their great contributions to the public in easy-to-understand language, turning science into a familiar and inseparable part of people's lives. At the same time, we would like to inspire youth to take on responsibility for pressing global issues, thereby encouraging them to pursue scientific research to find solutions." Previously, in September 2021, the first dialogue titled "How Science is Changing Global Health?" was successfully organized by VinFuture Foundation with the participation of world-leading scientists in the field of health management, such as Prof. Ezekiel Emanuel (Vice Provost for Global Initiatives at the University of Pennsylvania, USA), Professor Alta Schutte (Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine in the Faculty of Medicine and Health at the University of New South Wales, Sydney, Australia),... All VinFuture webinars will be open to the public free-of-charge via Zoom and Facebook: https://www.facebook.com/VinFuturePrize/ (Language: English). Register to participate in the event here. About VinFuture Foundation VinFuture Foundation is an independent and non-profit foundation operating in Vietnam. It was founded with the vision of creating meaningful changes in people's daily lives through the celebration of global technological innovations. The Foundation's core activity is awarding the annual VinFuture Prize for breakthrough scientific and technological innovations that have made or have the potential to create meaningful changes in people's lives. In addition, the Foundation will conduct many activities to accomplish its mission, such as funding research projects, collaborating in academic development, and promoting STEMM education. https://www.facebook.com/VinFuturePrize/ #VinFuture Contact Details Vingroup v.chidqd@vingroup.net Company Website https://www.vingroup.net/en

November 08, 2021 09:00 AM Eastern Standard Time

Image

American Kidney Fund Announces Support from GSK to Expand Awareness for Underrepresented Community Participation in Clinical Trials

American Kidney Fund

The American Kidney Fund (AKF) today announced that GSK has provided continued support to expand upon AKF’s efforts to increase participation of underrepresented communities in clinical trials. With GSK’s support, AKF will further enhance its clinical trials educational materials, including providing translations for new and existing content for Spanish-speaking audiences. This renewed effort will also include a video series, featuring Black and Hispanic kidney patients discussing their personal experiences as participants in clinical trials. “People of color, particularly Black and Hispanic individuals, continue to be underrepresented in clinical trial research studies for a number of reasons, which ultimately impacts research outcomes and the ability to uncover new options for patients,” said LaVarne A. Burton, AKF President and CEO. “With GSK’s funding, it is our hope that we can help people of color in their decision-making process when considering signing up for a clinical trial, as well as in speaking with their doctors about how they can be active participants in improving their own health and the future health of others.” GSK’s funding is a continuation of the support it has provided since 2019 to help AKF build a clinical trials awareness campaign, which supports AKF's broader strategy of addressing disparities and improving health equity in kidney disease care. “As part of our commitment to inclusion and diversity at GSK, we are ensuring that underrepresented patient populations are well represented in our clinical trials to make certain that our medications are safe and effective in a variety of patient groups,” said Precil Varghese, GSK Senior Medical Lead, Specialty and Pipeline. “We are proud to support AKF in its mission of educating the kidney disease community and historically underserved communities to help prevent and manage kidney disease.” About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck Work: +1 202-470-1797 Mobile: +1 978-390-1394 11921 Rockville Pike, Suite 300, Rockville, MD 20852 AKF@jpa.com Company Website https://www.kidneyfund.org/

November 04, 2021 09:00 AM Eastern Daylight Time

Improving the Lives of Caregivers

YourUpdateTV

There will be more people over 65 than under 18 by 2030 -- the boomer generation is living longer and wants to age at home. The result is more than 53 million family caregivers in the U.S., caring for more than 80 million people, and spending more than $187 billion on home health care. Recently, Bianca Padilla, CEO and Co-Founder of Carewell, participated in a nationwide satellite media tour to discuss the importance of supporting caregivers around the country. A video accompanying this announcement is available at: https://youtu.be/Z8i-N0yyx30 One-fifth of Americans will act as informal caregivers at some point in their lives, but there is little in the way of vetted products, product knowledge, guidance, and service to help those in the position of caring for a loved one. The biggest trend in caregiving over the past few years is aging at home. 90% of Americans want to stay in their homes for the rest of their lives. They don’t want change, and it’s up to the younger generations to help them do this safely and comfortably. 84% of caregivers report needing more information, so providing access to educational resources is vital for this audience, especially as conditions change - and usually worsen - over time. Carewell is redefining home healthcare by helping caregivers manage their loved one’s conditions, as well as their own lives. Carewell strives to make this population feel seen and understood by providing the products, service, and community support they need along with a level of customer service and convenience rarely found in healthcare. Carewell offers support to family caregivers with a library of information and caregiving guides to remove guesswork. For more information, visit Carewell.com About Bianca Padilla: Bianca Padilla is the CEO and co-founder of Carewell, a family-founded company that simplifies life for caregivers by providing personalized service, compassionate content, and expert-vetted home care products. A graduate of New York University with a B.A. in Economics, Bianca attended the Disney Institute and formed the Charlotte chapter of Aging 2.0, for which she currently serves as an ambassador. Prior to founding Carewell, Bianca worked as a software engineer at LiveNinja and as an analyst for CCMP Capital Advisors and Pantheon Ventures. A Miami native, Bianca enjoys spending time with her co-founder husband Jon and dog Henry, traveling, being an unabashed foodie, and reading books about entrepreneurship, leadership, tech, and comedy. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 03, 2021 02:00 PM Eastern Daylight Time

Video

American Kidney Fund Announces Major Support from AstraZeneca to Address Health Equity in Kidney Disease

American Kidney Fund

The American Kidney Fund (AKF) today announced that AstraZeneca is committing a major foundational investment to support AKF’s work to advance health equity by addressing racial disparities in kidney failure. With this investment, AstraZeneca deepens its partnership with AKF and provides critical support toward AKF’s goal of delivering more equitable kidney care for all. AstraZeneca’s support will allow AKF to develop a platform of programs, resources and policies that tackle health disparities faced by communities of color, who are disproportionately impacted by kidney failure. The partnership will expand AKF’s existing relationships with communities of color, organizations that represent and serve these communities and renal professionals. “Kidney disease impacts people of all backgrounds and demographics; however, people of color disproportionately progress to kidney failure due to inequities in our health care system,” said LaVarne A. Burton, AKF President and CEO. “AKF is grateful to AstraZeneca for again partnering with us to tackle health disparities and provide kidney patients, especially those in underserved communities, with an equitable opportunity to attain their full health potential.” “AstraZeneca is committed to addressing health disparities and ensuring every patient who is a part of the kidney disease community has an equal opportunity to be as healthy as possible,” said Martha Orzechowski, Head of US Advocacy and Alliance at AstraZeneca. “We are honored to continue our partnership with the American Kidney Fund on this important effort to help eliminate discrimination from the delivery of health care.” About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck 202-470-1797 +1 978-390-1394 AKF@jpa.com Company Website https://www.kidneyfund.org/

November 03, 2021 09:00 AM Eastern Daylight Time

1 ... 245 246 247 248 249 ... 302